Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup

Oncology Letters
Antonio IeniGiovanni Tuccari

Abstract

Triple-negative breast cancer (TNBC) indicates a subset of breast carcinomas that does not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2). According to the literature, TNBCs are aggressive tumors, characterized by a high incidence of recurrence and a high risk of disease progression. Lactoferrin (LF) is a single-chain, iron-binding glycoprotein of ~700 amino acids, which is involved in a wide range of biological activities, including iron-trafficking and carcinogenesis. The present study aimed to assess LF expression in human TNBC samples and the possible correlation with clinico-pathological parameters associated with biological aggressiveness. LF immunohistochemical expression was investigated in formalin-fixed, paraffin-embedded samples of human TNBC. Cases were analyzed according to an intensity distribution (ID) score, and only those showing an ID score of >2 were considered as positive for LF. LF immunostaining was encountered in 26.15% cases. A significant correlation was found between LF expression and a low Ki-67 labeling index (P=0.040), the absence of recurrence (P=0.010) and alive status (P=0.020). LF may assist in identifying a subset of TNBC with less...Continue Reading

References

Jan 1, 1985·Virchows Archiv. A, Pathological Anatomy and Histopathology·G Tuccari, G Barresi
Nov 16, 2004·International Journal of Cancer. Journal International Du Cancer·Monique BenaïssaAnnick Pierce
Apr 13, 2005·European Journal of Histochemistry : EJH·G TuccariG Barresi
Dec 6, 2006·Cancer·Emad A RakhaIan O Ellis
Feb 26, 2009·Journal of Bone and Mineral Metabolism·Antonio IeniGiovanni Tuccari
Dec 10, 2009·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Antonio IeniGiovanni Tuccari
Jun 17, 2010·British Journal of Cancer·S KashiwagiK Hirakawa
Sep 4, 2010·Breast Cancer Research : BCR·Aleix PratCharles M Perou
Feb 10, 2011·The Oncologist·Charles M Perou
Apr 8, 2011·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Giovanni Tuccari, Gaetano Barresi
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Oct 14, 2014·Archives of Pathology & Laboratory Medicine·Damoun Safarpour, Fattaneh A Tavassoli
Dec 3, 2014·Annals of Diagnostic Pathology·Mona A Abd-Elazeem, Marwa A Abd-Elazeem

❮ Previous
Next ❯

Citations

Apr 25, 2020·Frontiers in Oncology·Rikki A M BrownPeter J Leedman
Dec 9, 2020·Cells·Myriam Y HsuPaolo E Porporato
Jan 25, 2021·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Zheng ZhangLi-Qiang Qin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.